Nafulizumab
NSCLC Patients
Fudan UniversityN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1206 Active assets in the NSCLC Patients cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Necitumumab Jonsson Comprehensive Cancer Center | Phase 3 | BBB |
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd. | Phase 2/3 | BBB |
Glumetinib Shanghai JMT-Bio Inc. | Phase 3 | BBB |
d-0316 Betta Pharmaceuticals Co., Ltd. | Phase 2/3 | BBB |
Onartuzumab Hoffmann-La Roche | Phase 3 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →